Abstract
Background
The last 5 years have seen the emergence and establishment of antibodies to citrullinated antigens as the diagnostic marker for rheumatoid arthritis (RA). Initially, these were detected using a synthetic peptide, which has undergone a number of modifications to give a diagnostic test with a sensitivity of 65–80% and a specificity of >95%. Antibodies to citrullinated vimentin were first described in 1994 as a highly specific marker for RA (anti-Sa). However, no easily performed assay for these antibodies has been available.
Methods
We have examined the use of a ELISA-based assay with a mutated citrullinated vimentin (MCV) antigen (Orgentec, Mainz, Germany) to assess the diagnostic and prognostic utility of this antibody in RA.
Results
Antibodies to MCV were detected in the sera of 74% RA patients (specificity 96%), 2% systemic lupus erythematosus, 14% Sjögren’s syndrome, and 2% scleroderma. Anti-MCV was not detected in sera from healthy blood donors. There was no difference in the frequency of antibodies detected in RA patients with early (<2 years) or chronic (>2 years) disease. There was no significant variation in anti-MCV antibody concentrations in early RA patients over a 52-week period. No significant change was observed with time between the two treatment groups of methotrexate alone or methotrexate plus infliximab.
Conclusions
Antibodies to MCV are a specific and sensitive marker for the diagnosis of RA.
Similar content being viewed by others
References
Huizinga TWJ, Landewé RBM (2005) Nat Clin Pract Rheum 1(1):2–3
Arnett FC, Edworthy SM, Bloch DA et al (1988) Arthritis Rheum 31:315–324
Cruyssen BV, Cantaert T, Nogueira L et al (2006) Arthritis Res Ther 8:R122
Kinloch A, Tatzer V, Wait R et al (2005) Arthritis Res Ther 7:R1421–R1429
Vossenaar ER, Radstake TR, Van Der Heijden A et al (2004) Ann Rheum Dis 63:373–381
Tak PP, Smeets TJ, Daha MR et al (1997) Arthritis Rheum 40:217–225
Zendman AJW, van Venrooij WJ, Pruijn GJM (2006) Rheumatology 45:20–25
Tarcsa E, Marekov LN, Mei G et al (1996) J Biol Chem 271:30709–30716
Lundberg K, Nijenhuis S, Vossenaar E et al (2004) Arthritis Res Ther 6(Suppl 1):18 (Abstract)
Hill JA, Southwood S, Sette A et al (2003) J Immunol 171:538–541
van Gaalen F, Ioan-Facsinay A, Huizinga TWJ et al (2005) J Immunol 175:5575–5580
Masson-Bessiere C, Sebbag M, Durieux JJ et al (2000) Clin Exp Immunol 119:544–552
Makrygiannakis D, af Klint E, Lundberg IE et al (2006) Ann Rheum Dis 65:1219–1222
Young BJ, Mallya RK, Leslie RD et al (1979) Br Med J 14:97–99
Simon M, Girbal E, Sebbag M et al (1993) J Clin Invest 92:1387–1393
Sebbag M, Simon M, Vincent C et al (1995) J Clin Invest 95:2672–2679
Girbal-Neuhauser E, Durieux JJ, Arnaud M et al (1999) J Immunol 162:585–594
van Venrooij WJ, Pruijn GJM (2000) Arthritis Res 2:249–251
Nielen MMJ, van der Horst AR, van Schaardenburg D et al (2005) Ann Rheum Dis 64:1199–1204
Schellekens GA, de Jong BA, van den Hoogen FH et al (1998) J Clin Invest 101:273–281
Quinn MA, Gough AK, Green MJ et al (2006) Rheumatology 45(4):478–480
van Gaalen FA, Visser H, Huizinga TWJ (2005) Ann Rheum Dis 64:1510–1512
Takasaki Y, Yamanaka K, Takasaki C et al (2004) Mod Rheumatol 14(5):367–375
Vannini A, Cheung K, Fusconi M et al (2006) Ann Rheum Dis (published online http://ard.bmj.com/cgi/content/abstract/ard.2006.058933v1)
Rantapaa-Dahlqvist S, de Jong BA, Berglin E et al (2003) Arthritis Rheum 48(10):2701–2705
Van Gaalen FA, Linn-Rasker SP, van Venrooij WJ et al (2004) Arthritis Rheum 50(3):709–715
Berglin E, Padyukov L, Sundin U et al (2004) Arthritis Res Ther 6:R303–R308
van der Helm-van Mil AHM, Verpoort KN, Breedveld FC et al (2005) Arthritis Res Ther 7(5):R949–R958
Berglin E, Johansson T, Sundin U et al (2006) Ann Rheum Dis 65(4):453–458
Inanc N, Dalkilic E, Kamali S et al (2007) Clin Rheumatol 26(1):17–23
Despres N, Boire G, Lopez-Longo FJ et al (1994) J Rheumatol 21(6):1027–1033
Menard HA, Lapointe E, Rochdi MD et al (2000) Arthritis Res 2:429–432
Hueber W, Hassfeld W, Smolen JS et al (1999) Rheumatology 38:155–159
Hayem G, De Bandt M, Palazzo E et al (1999) J Rheumatol 26:7–13
Vossenaar ER, Despres N, Lapointe E et al (2004) Arthritis Res Ther 6(2):R142–R150
Boire G, Cossette P, de Brum-Fernandes AJ et al (2005) Arthritis Res Ther 7:R592–R603
Bang H, Lûthke K, Gauliard A et al (2006) Ann Rheum DIs 65(Suppl II):144 (Abstract)
Lakos G, Soos L, Szabo Z et al (2006) Abstract THU0118, EULAR
Klotz W, Dejaco C, Larcher H et al (2006) Abstract FRI0050, EULAR
Brickmann KP, Yazdani-Biuki BJ, Graninger M et al (2006) Abstract SAT0431, EULAR
Dejaco C, Klotz W, Larcher H et al (2006) Arthritis Res Ther 8:R119–R124
Hassfeld WG, Vinje O, König K et al (2006) Abstract FR10513, EULAR
Brickmann K, Yazdani-Biuki BJ, Mûller T et al (2006) Abstract AB0492, EULAR
Egerer K, Bang H, Gauliard A et al (2006) Poster presented at EULAR
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Poulsom, H., Charles, P.J. Antibodies to Citrullinated Vimentin are a Specific and Sensitive Marker for the Diagnosis of Rheumatoid Arthritis. Clinic Rev Allerg Immunol 34, 4–10 (2008). https://doi.org/10.1007/s12016-007-8016-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12016-007-8016-3